CAPTRUST Financial Advisors’s Northwest Biotherapeutics NWBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-17,624
Closed -$11K – 4734
2022
Q2
$11K Buy
17,624
+11,334
+180% +$7.07K ﹤0.01% 3720
2022
Q1
$4K Hold
6,290
– – ﹤0.01% 4315
2021
Q4
$4K Hold
6,290
– – ﹤0.01% 4227
2021
Q3
$8K Sell
6,290
-1,500
-19% -$1.91K ﹤0.01% 3775
2021
Q2
$11K Hold
7,790
– – ﹤0.01% 3523
2021
Q1
$12K Buy
7,790
+2,938
+61% +$4.53K ﹤0.01% 3356
2020
Q4
$7K Buy
4,852
+190
+4% +$274 ﹤0.01% 2736
2020
Q3
$3K Buy
4,662
+2,500
+116% +$1.61K ﹤0.01% 2714
2020
Q2
$1K Buy
+2,162
New +$1K ﹤0.01% 2796
2019
Q4
– Sell
-6,000
Closed -$1K – 2097
2019
Q3
$1K Hold
6,000
– – ﹤0.01% 1903
2019
Q2
$2K Sell
6,000
-3,200
-35% -$1.07K ﹤0.01% 1839
2019
Q1
$3K Buy
+9,200
New +$3K ﹤0.01% 1666

Other funds holding NWBO

CAPTRUST Financial Advisors's NWBO Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Northwest Biotherapeutics (NWBO) in Q3 2022, closing a stake of 17,624 shares — an estimated $11K sold.

CAPTRUST Financial Advisors first reported a position in NWBO in Q1 2019 and held it in 12 quarters. The position peaked at $12K in Q1 2021. 13 funds tracked by Wall St. Rank hold NWBO as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Northwest Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 17,624 Northwest Biotherapeutics shares in Q3 2022, an estimated $11K.
  • CAPTRUST Financial Advisors first reported a position in Northwest Biotherapeutics in Q1 2019 and held it in 12 quarters.
  • CAPTRUST Financial Advisors's Northwest Biotherapeutics position peaked at $12K in Q1 2021.
  • 13 funds tracked by Wall St. Rank held Northwest Biotherapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.